VIDEO: Speaker offers updates on combinations, sequencing of immunotherapies for melanoma

Source: Healio, April 2017

NEW YORK — Michael A. Postow, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, addressed the use of immune checkpoint inhibitors at HemOnc Today Melanoma and Cutaneous Malignancies.

He focused his discussion of the most effective treatment options around a case presentation of a 52-year-old man with BRAF wild-type esophageal melanoma.

Factors that may affect an oncologist’s decision between single-agent PD-1 therapy and combination therapy include comorbidities, contraindications to steroids or immunosuppression, pace and disease burden, and patient communications with health care providers.